Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Sales | 11,133 | 3,835 | 299 | 58 | 89 |
| Cost of Goods | 3,663 | 1,085 | 21 | N/A | N/A |
| Gross Profit | 7,470 | 2,750 | 278 | 58 | 89 |
| Operating Expenses | 86,102 | 79,963 | 57,404 | 61,018 | 46,259 |
| Operating Income | -77,969 | -77,128 | -57,105 | -60,960 | -46,170 |
| Interest Expense | 4,410 | 4,334 | 4,256 | 2,148 | 0 |
| Other Income | 1,350 | 205 | 771 | 1,275 | 844 |
| Pre-tax Income | -81,029 | -81,257 | -60,590 | -61,833 | -45,326 |
| Income Tax | -2,720 | N/A | N/A | 100 | N/A |
| Net Income Continuous | -78,309 | -81,257 | -60,590 | -61,933 | -45,326 |
| Net Income | $-78,309 | $-81,257 | $-60,590 | $-61,933 | $-45,326 |
| EPS Basic Total Ops | -1.25 | -1.34 | -1.12 | -1.15 | -1.00 |
| EPS Basic Continuous Ops | -1.25 | -1.34 | -1.12 | -1.15 | -1.00 |
| EPS Diluted Total Ops | -1.25 | -1.34 | -1.12 | -1.15 | -1.00 |
| EPS Diluted Continuous Ops | -1.25 | -1.34 | -1.12 | -1.15 | -1.00 |
| EBITDA(a) | $-70,572 | $-70,517 | $-53,291 | $-59,229 | $-45,835 |